Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12776)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 14, 2019 (publication date) through Jun 29, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Limanskiy V, Vyas A, Chaturvedi LS, Vyas D. Harnessing the potential of gene editing technology using CRISPR in inflammatory bowel disease. World J Gastroenterol 2019; 25(18): 2177-2187 [PMID: 31143069 DOI: 10.3748/wjg.v25.i18.2177] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i18/2177.htm |
| Number | Citing Articles |
| 1 |
Shahad K. Alsaiari, Behnaz Eshaghi, Bujie Du, Maria Kanelli, Gary Li, Xunhui Wu, Linzixuan Zhang, Mehr Chaddah, Alicia Lau, Xin Yang, Robert Langer, Ana Jaklenec. CRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells. Nature Reviews Materials 2024; 10(1): 44 doi: 10.1038/s41578-024-00725-7
|
| 2 |
Rui Wang, Sean Graham, Ning Sun, Donna McCarthy, Ruoqi Peng, Jamie Erickson, Liz Oconnor, Xiaochun Zhu, Marc Wurbel, Robert Dunstan, Susan Westmoreland, Namjin Chung, Tariq Ghayur, Jijie Gu, Edda Fiebiger. CRISPR/Cas9-targeting of CD40 in hematopoietic stem cells limits immune activation mediated by anti-CD40. PLOS ONE 2020; 15(3): e0228221 doi: 10.1371/journal.pone.0228221
|
| 3 |
Xiaoting Xu, Yuping Zhang, Guoxin Huang, Ansu Perekatt, Yan Wang, Lei Chen. Advances and applications of gut organoids: modeling intestinal diseases and therapeutic development. Life Medicine 2025; 4(2) doi: 10.1093/lifemedi/lnaf012
|
| 4 |
Aravind Sundararaman, Prakash M. Halami. Genome editing of probiotic bacteria: present status and future prospects. Biologia 2022; 77(7): 1831 doi: 10.1007/s11756-022-01049-z
|
| 5 |
Miao Wu, Niandan Hu, Xianjin Du, Jie Wei. Application of CRISPR/Cas9 technology in sepsis research. Briefings in Functional Genomics 2020; 19(3): 229 doi: 10.1093/bfgp/elz040
|
| 6 |
Martina Poletti, Kaline Arnauts, Marc Ferrante, Tamas Korcsmaros. Organoid-based Models to Study the Role of Host-microbiota Interactions in IBD. Journal of Crohn's and Colitis 2021; 15(7): 1222 doi: 10.1093/ecco-jcc/jjaa257
|
| 7 |
Sidra Anwar, Alvina Gul, Rumeza Hanif. Targeted Genome Engineering via CRISPR/ Cas9 in Plants. 2024; : 21 doi: 10.1016/B978-0-443-26614-0.00014-X
|
| 8 |
Zahra Khademi, Negar Mottaghi-Dastjerdi, Hamed Morad, Amirhossein Sahebkar. The role of CRISPR-Cas9 and CRISPR interference technologies in the treatment of autoimmune diseases. Autoimmunity Reviews 2025; 24(7): 103816 doi: 10.1016/j.autrev.2025.103816
|
| 9 |
|
| 10 |
Yingying Chen, Dongyue Li, Liying Sun, Kai Qi, Lijun Shi. Pharmacological inhibition of toll-like receptor 4 with TLR4-IN-C34 modulates the intestinal flora homeostasis and the MyD88/NF-κB axis in ulcerative colitis. European Journal of Pharmacology 2022; 934: 175294 doi: 10.1016/j.ejphar.2022.175294
|